Phuturdex › Diseases › Systemic scleroderma
Drugs in development · updated 30 October 2026
Systemic scleroderma: drugs in development
As of 30 October 2026 there are 71 active clinical trials (recruiting or ongoing, phases I–III) on 77 drugs for systemic scleroderma. 50 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 50 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CyclophosphamideCyclophosphamid, Cytoxan | III | 12 | NCT07335562 |
| FludarabineFludara, FLUDARABIN | III | 10 | NCT07335562 |
| RituximabRuxience, Rituxan | III | 4 | NCT07335562 |
| TocilizumabTociluzumab, Avtozma | III | 4 | NCT07335562 |
| BelimumabBenlysta® | II–III | 2 | NCT05878717 |
| NerandomilastBI 1015550, Jascayd® | III | 2 | NCT07497087 |
| NintedanibNintedanib Accord®, Vargatef® | III | 2 | NCT07335562 |
| CannabidiolEpidiolex, Epidyolex® | III | 1 | NCT07245238 |
| ClopidogrelClopidgrel, Clopidogrel Zentiva (previously Clopidogrel Winthrop)® | II–III | 1 | NCT05098704 |
| InebilizumabUplizna® | III | 1 | NCT05198557 |
| UreaSterile Urea®, Ureaphil® | III | 1 | NCT07245238 |
| Mycophenolate MofetilMycophenolate, Cellcept | II | 2 | NCT07734012 |
| AlemtuzumabCampath, Lemtrada® | II | 1 | NCT03630211 |
| Anti-Thymocyte Globulin | II | 1 | NCT03630211 |
| MesnaUromitexan, Mesnex® | II | 1 | NCT03630211 |
Sorted by most advanced phase and number of active trials. Showing 15 of 27 drugs.
All 77 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Diffuse scleroderma 39 drugs
- Interstitial lung disease 65 drugs
- Anti-neutrophil cytoplasmic antibody-associated vasculitis 35 drugs
- Connective tissue disease 21 drugs
- Systemic lupus erythematosus 178 drugs
- Myositis 42 drugs
- Lupus nephritis 64 drugs
- Pulmonary fibrosis 34 drugs
- Rheumatoid arthritis 130 drugs
- Sarcoidosis 10 drugs
- Fibrosis 52 drugs
Broader categories
- Skin and connective tissue diseases 3 drugs
- Connective tissue disease 21 drugs
- Skin disease 34 drugs
- Immune System Diseases 54 drugs
- Musculoskeletal disorder 22 drugs
- Nervous System Diseases 39 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D012595 “Scleroderma, Systemic”. Prevalence: Orphanet.